Book Value per Share: 89bio.com (ETNB)

Graphic logo of 89bio, Inc. (ETNB)

Business development for 89bio, Inc. (ETNB) is independent of the economy, as the primary catalysts are the tests for steatohepatitis treatments. Management remains transparent regarding research, yet scaling sales will require alliances with industry behemoths. A visualization of financial quotes with the 3.52 indicator is available below. The company's fate rests on FDA approval and the success of clinical trials for liver and metabolic drugs.

89bio Inc (ETNB): Share Book Value from 07/04/2022 to 11/15/2025

89bio.com - analytical breakdowns and key metrics (ETNB)

- price and consensus price forecast:
Price Chart 89bio Corp|ETNB - Broker Consensus Forecast
- market capitalization data:
Market Capitalization 89bio, Inc.|ETNB - Total Company Value
- book capitalization data:
Net Assets per Single Share 89bio|ETNB - Net Asset Value|Market Capitalization to Book Value Ratio 89bio.com|ETNB - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital 89bio, Inc.|ETNB - Long-Term Debt to Capital|Short-Term Debt to Equity 89bio|ETNB - Aggregate Debt Obligations|Debt to Book Capitalization Ratio 89bio, Inc.
Fundamental company valuation:89bio Corp - ETNB
Manufactured products of 89bio

Defensive assets are selected based on the balance sheet's ability to withstand systemic shocks, which is critical for 89bio, Inc. (ETNB) due to high R&D expenditures and the absence of stable revenue. This metric reflects the equity per share, measuring the actual value of net assets. The price action of the company's book value per share visualizes the capitalization process between reports. Growth in this indicator confirms financial stability amidst the risk of clinical trial failure.

Competitors of 89bio, Inc. (ETNB)

Ascendis Pharma Inc. (ASND) - Net Assets per Single Share|MDGL - Equity per Share|Corcept Therapeutics (CORT) - Book Value per Share|RYTM (rhythmtx.com) - Net Assets per Single Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|AGIO: Accounting Value of a Share|GPCR (Structure Pharma) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS